Pharma sector: what’s new for EU and UK merger control?


Competition team partner Stephen Smith and associates Edwin Bond and Isobel Thomas provide a general overview of the EU and UK merger control regimes, discussing key issues in relation to the pharma sector such as market definition, price and innovation effects of horizontal mergers, remedies, and proposals to amend the UK merger control regime.

Read the full PDF article here.

Reproduced from Practical Law with the permission of the publishers. For further information visit

Note: In December 2022 Stephen Smith, Sean-Paul Brankin and Edwin Bond, updated this overview to reflect changes in the law. Read the new version here.

Stephen Smith


Edwin Bond


Isobel Thomas

Related Articles